Clinical Trials Logo

Clinical Trial Summary

The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of therapy with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) in adults with chronic hepatitis C virus (HCV) infection and compensated cirrhosis.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04112303
Study type Interventional
Source Gilead Sciences
Contact
Status Completed
Phase Phase 3
Start date October 16, 2019
Completion date June 25, 2021

See also
  Status Clinical Trial Phase
Completed NCT02487030 - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection Phase 3
Active, not recruiting NCT05460130 - Implementing HCV Treatment for High-risk Populations in Austin, Texas N/A
Completed NCT02220998 - Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection Phase 3
Terminated NCT01052090 - Safety and Efficacy Study in Hepatitis C Patients With PHN121 Phase 1/Phase 2
Completed NCT02537379 - Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection N/A
Recruiting NCT04156945 - Interventions to Curb Hepatitis C Reinfections Among Men Who Have Sex With Men N/A
Terminated NCT02510300 - A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
Withdrawn NCT04309734 - Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects Phase 1/Phase 2
Active, not recruiting NCT04001608 - Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients Phase 3
Completed NCT02251717 - Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection Phase 2
Recruiting NCT05092074 - Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection
Recruiting NCT04005248 - Prevalence of HCV in HIV-negative MSM N/A
Completed NCT02249182 - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection Phase 2
Completed NCT02939989 - Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study Phase 3
Completed NCT01718145 - A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects Phase 3
Completed NCT01482611 - A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382 Phase 1
Completed NCT00255177 - Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients Phase 2
Terminated NCT02600351 - Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies Phase 3
Completed NCT04980157 - CARES-HCV: Promoting Screening Uptake Among Diverse Baby Boomers
Completed NCT02350569 - Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting Phase 2